Table 3 Baseline demographic and clinical features of RA and OA patients in the study of PGC-1β expression in FLS by qPCR and western blot
Characteristic | RA patients (n = 8) | OA patients (n = 6) |
|---|---|---|
Demographic | Â | Â |
Age, yrs, median (range) | 55 (33 to 70) | 57 (51 to 68) |
Female, n (%) | 8 (100) | 6 (100) |
Disease status | Â | Â |
Disease duration, mo, median (range) | 78 (2 to 240) | 36 (12 to 168) |
ESR, mm/h, median (range) | 50 (11 to 83) | 18 (12 to 32) |
CRP, mg/dl, median (range) | 1.53 (0.02 to 4.55) | 0.33 (0.08 to 1.11) |
Rheumatoid factor-positive, n (%) | 7 (87.5) | NA |
Anti-CCP-positive, n (%) | 8 (100) | NA |
DAS28, median (range) | 4.36 (3.06 to 5.82) | NA |
Previous medications, n (%) | Â | NA |
Corticosteroids | 3 (37.5) | NA |
Methotrexate | 4 (50) | NA |
Leflunomide | 3 (37.5) | NA |
Hydroxychloroquine | 2 (25) | NA |
Infliximab | 1 (12.5) | NA |
Etanercept | 1 (12.5) | NA |